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A B S T R A C T
Nanocapsules (NCs) have become one of the most researched nanostructured drug delivery systems due to their
advantageous properties and versatility. NCs can enhance the bioavailabiliy of hydrophobic drugs by impoving
their solubility and permeability. Also, they can protect these active pharmaceutical agents (APIs) from the
physiological environment with preventing e.g. the enzymatic degradation. NCs can be used for many admin-
istration routes: e.g. oral, dermal, nasal and ocular formulations are exisiting in liquid and solid forms. The nose
is one of the most interesting alternative drug administration route, because local, systemic and direct central
nervous system (CNS) delivery can be achived; this could be utilized in the therapy of CNS diseases. Therefore,
the goal of this study was to design, prepare and investigate a novel, lamotrigin containing NC formulation for
nasal administration. The determination of micrometric parameters (particle size, polydispersity index, surface
charge), in vitro (drug loading capacity, release and permeability investigations) and in vivo characterization of
the formulations were performed in the study. The results indicate that the formulation could be a promising
alternative of lamotrigine (LAM) as the NCs were around 305 nm size with high encapsulation efficiency
(58.44%). Moreover, the LAM showed rapid and high release from the NCs in vitro and considerable penetration
to the brain tissues was observed during the in vivo study.
1. Introduction
In the last decade, encapsulation of Active Pharmaceutical
Ingredients (APIs) has become increasingly important due to its ad-
vantages over traditional technological methods for solubilization (e.g.
solid dispersions, ammorphization). Indeed, some nanocarriers can
improve the solubility of hydrophobic drugs and thereby enhance their
bioavailability [1–3]. Nanocapsules (NCs) consist of an oily core and a
biodegradable polymer shell. This structure can protect the APIs from
the physiological environment (e.g. pH, enzymatic degradation) and
enhance their permeability through biological barriers [4–8]. Further
advantages are that the NCs can reduce drug toxicity and increase their
stability. NCs have been developed for different administration routes.
Among these routes the oral and the parenteral routes are the most
researched, but there have been some efforts to prepare dermal, ocular
or nasal formulations [9–19].
Nasal delivery is an alternative route for drug administration and
has become increasingly investigated in the last years. Via the nasal
route drugs can be delivered locally, systemically, but also directly into
the central nervous system (CNS), which is the unique property of nasal
administration. This is a barely understood mechanism for the direct
transport of drugs from nose-to-brain that overcomes the blood-brain-
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barrier (BBB) [15–25]. Therefore, in the case of CNS diseases, the nasal
route can be an attractive way to deliver APIs directly into the CNS by a
non-invasive way [26–34]. Other advantages are that the administra-
tion for nose-to-brain delivery is not painful and sterility is not a for-
mulation requirement [26,35]. In the literature some articles could be
found, where e.g. statin or benziodiazepine containing NCs were in-
vestigated via nasal route [36–38]. In these studies the researchers
aimed to develop and investigate these formulations in vivo and the
APIs presented in the brain tissues after nasal administration of NCs, so
they could be suitable for the treatment of other diseases.
Lamotrigine (LAM) is a poorly water soluble, second generation
antielpileptic drug from the phenyltriazine class, that is currently
available only in tablet form [39–43]. It has been applied in many in
vivo studies, but there the aims were to evaluate its immunmodulatory
effect [44,45], bioactivation [46], formulation of gastroretentive matrix
tablets, chewable/dispersible tablets [47,48] or iv. nanoformaultion
[41]. Also, there was a study, in which LAM was used intranasally, but
there the goal was to determine the phamarcokinetic properties of the
API [34].
Our research group has made successful efforts to develop nasal
powder form of LAM with a top-down method [49,50]. As the nose is a
great alternative administration route to allocate APIs directly into the
CNS and provides great possibilty to take advantage of NCs, we en-
visage that a novel, NC formulation made with a bottom-up method
could improve the interaction between the drug and the nasal epithe-
lium. Thus the advantages of the nasal delivery and NCs could be
combined [19,51–53]. Therefore, the aims of this study were to design
and prepare LAM-loaded chitosan NC formulations for nasal drug de-
livery. For this, we optimized the preparation method of the formula-
tions, we characterized the NCs properties and studied their delivery
performance under in vitro and in vivo conditions.
2. Materials and methods
2.1. Identification of factors affecting product quality
Quality by Design (QbD) is a holistic and systematic quality man-
agement technique, where the development design is knowledge and
based; thus, the experiments can be planned more efficiently and eco-
nomically. As part of the QbD methodology, an Ishikawa diagram was
set up to identify a knowledge space of the NCs. With the Ishikawa
diagram, the identification and systematization of influencing factors
were carried out. The factors with the highest influence were chosen
and varied [49,54].
2.2. Materials
LAM, was purchased from Teva Ltd. (Budapest, Hungary). Glyceryl
monooleate (Type 40) (Peceol®) and Diethylene glycol monoethyl ether
(Transcutol HP®) were a kind gift from Gattefossé (St. Preist, France).
Polyoxyetylene (40) monostearate (PEG-stearate 40) was purchased
from Croda (East Yorkshire, United Kingdom). Chitosan hydrochloride
salt was obtained from HMC+ (Halle, Germany). Mannitol was ob-
tained from Sigma-Aldrich (New York, USA).
2.3. Methods
2.3.1. Preparation of nanocapsules (NCs)
The NCs were prepared by a solvent displacement method, whose
compositition (Table 1) was optimized after preliminary experiments.
The liquid lipid: surfactant ratio was varied on 3 levels (2:1, 1:1 and
1:2), of which the 1:1 ratio showed proper in terms of particle size, PDI
and surface charge. In this sample, the organic phase was first prepared
by adding the adeaquate amount of LAM solution (100 mg/mL DMSO
solution), Peceol® and Transcutol® to PEG-stearate 40 solution
(5.33 mg/mL ethanol solution). Then, this solution was poured over
2 mL of ultrapure water under continous magnetic stirring to from an o/
w emulsion. After 10 min, 2 mL of chitosan solution (1 mg/mL) was
added upon this emulion under magnetic stirring, leading to the
spontaneous formation of the NCs.
After 10 additional minutes of stirring, the NCs were isolated and
concentrated to a final theoretical chitosan concentration of 1 mg/ml
by centrifugation (Hettich Universal 32 R; Tuttlingen, Germany) at
33000xg for 33 min at 15 °C. In parallel, control blank NCs, without
LAM were prepared using the same method.
2.3.2. Preparation of freeze-dried nanocapsules (FDNCs)
The freeze-drying was performed in Scanvac CoolSafe 100-9 Pro
type equipment (LaboGene ApS, Lynge, Denmark) equipped with a 3-
shelf sample holder unit, recessed into the drying chamber. The pre-
pared NCs were lyophilized with 5% mannitol. The process was con-
trolled by a computer program (Scanlaf CTS16a02), the temperature
and pressure values were recorded continuously. In the first period of
the freeze-drying the chamber was cooled from room temperature to
−25 °C. At this time the vacuum was turned on (p = 0,013 mBar).
Then the samples were kept under these conditions for 12 h, whileafter
during the secondary drying the temperature was raised up to +25 °C.
temperature. The secondary drying lasted for 4 h to produces the final
solid phase prodcuts (FDNCs). Fig. 1. illustrates the process of the NC
preparation.
2.3.3. Particle size, particle size distribution and surface charge
characterization of NCs
The particle size and polydispersity index of the NCs were de-
termined by photon correlation spectroscopy (PCS) (Zetasizer NanoZS®,
Malvern Instruments; Malvern, United Kingdom). In the case of surface
charge, zeta potential (ZP) measurements were done by laser Doppler
anemometry (LDA) using the same equipment. All the measurements
were performed at 25 °C with a detection angle of 173° in distilled
water, unless otherwise indicated. The freeze-dried NCs were in-
vestigated with the same instrument after redispergation with MilliQ
water. The FDNCs samples were investigated after resuspension in
MilliQ water.
2.3.4. Encapsulation efficacy (EE) and drug loading (DL)
After centrifugation the supernatant was analyzed for the amount of
drug present with a UV spectrophotometer (SynergyTM H1 Microplate
Reader, BioTek Instruments, Inc.) at λmax of 307 nm after suitable di-
lution. EE% was calculated by the following equation:
The calculation of encapsulation efficacy
= −
−
∗%EE ((W W )/W ) W W
W
1001 2 1 1 2
2 (1)
Loading capacity (percentage drug loading [%DL]) was calculated
by the following equation:
The calculation of percentage of drug loading
= − − +
−
∗%DL ((W W )/(W W W )) W W
W
1001 2 1 2 lipid 1 2
2 (2)
where, W1, W2 and Wlipid are the weight of drug added in the
Table 1
The compositition of the NC formulations.
1:1 2:1 1:2 + 2 mL
MilliQ
water
+ 2 mL 1 mg/ml
Chitosan solution
after 10 minsLAM solution(100 mg/
ml) (μL)
100 100 100
Peceol® (μL) 41.7 83.4 41.7
Transcutol®(μL) 41.7 41.7 83.4
PEG-stearate 40
solution (5.33 mg/
mL EtOH solution)
816.6 774.9 774.9
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formulation, analyzed weight of drug in supernatant and weight of lipid
added in formulation, respectively.
2.3.5. Morphology of NCs
For the SEM investigation, NC formulation were diluted and dried.
The morphology of NCs was investigated by SEM (Hitachi S4700;
Hitachi Ltd., Tokyo, Japan) at 10 kV. The samples were gold–palladium
coated (90 s) with a sputter coater (Bio- Rad SC502; VG Microtech,
Uckfield, UK) using an electric potential of 2.0 kV at 10 mA for 10 min.
The air pressure was 1.3–13.0 mPa. To confirm the particle size mea-
surements obtained by PCS (Section 2.3.5), the size of the freeze-dried
NCs were obtained by analyzing SEM images with the ImageJ software
(1.50i; Java 1.6.0_20 [32-bit]; Windows NT) using approximately 500
particles.
2.3.6. In vitro drug release study
The modified paddle method (USP dissolution apparatus, type II;
Pharma Test, Hainburg, Germany) was used to examine the dissolution
rate of LAM-containing NCs and determine the drug release profile from
the samples. To model the nasal pH and temperature conditions, the
medium was 9 mL phosphate-buffered saline (PBS) adjusted to pH 5.60.
Samples with 1.65 mg (n = 3) LAM content were tested in this medium
at 30 °C with paddle stirring at 50 rpm. The sampling points were at
5 min, 10 min, 15 min, 30 min, 45 min and 60 min. After each sampling
point, the medium was made up to 9 mL. The first data points were
considered the most important as the mucociliary clearance renews the
mucus every 15 min. The following data points offered additional in-
formation about the dissolution behavior of LAM. The samples were
investigated with a RP-HPLC-DAD system. The RP-HPLC-DAD was
consisted of an Agilent 1200 Series chromatograph and a DAD detector.
The statonary phase was a Kinetex® C18 colonna (150 mm × 4,6 mm,
particle size: 5 μm, pore diameter size: 100 Å). The separation was
isocratic, the composition of the mobile phase was 0,01 M phosphate
buffer (pH= 6,7 ± 0,1): methanol: acetonitrile = 50:20:30 (v/v). The
analytical column was tempered for 25 °C and the measurements lasted
10 mins. The flow rate was 0.75 mL/min, and 10 µL of sample was
injected into the flowing fluid, measured at 307 nm. The equation for
the calibration line was: y = 12,335x − 3,488 (R2 = 1). The equation
was valid in the range of 10–150 μg/ml. The tests were carried out in
triplicates.
2.3.7. In vitro permeability study
The horizontal diffusion test (Side-Bi-Side™, Crown Glass, USA) was
carried out under simulated nasal conditions (pH 5.6, 30 °C). The tested
samples (n = 3) contained 1.65 mg LAM. The cellulose ester membrane
with 0.45 μm pore diameter was soaked in isopropyl myristate 30 min
before the investigation, and the donor phase was tempered to 30 °C at
pH 5.6. The powder samples were washed into the chamber with the
medium of the donor phase in the beginning of the study. The acceptor
phase was at pH 7.4, and the concentration of diffused API was mea-
sured spectrophotometrically in real time at 307 nm with an AvaLight
DH-S-BAL spectrophotometer (AVANTES, Netherlands) connected to an
AvaSpec-2048L transmission immersion probe (AVANTES, Netherland)
with optical fiber. The path length was 1 cm. The tests were carried out
in triplicate.
2.3.8. In vivo studies
2.3.8.1. Intranasal administration, blood sample collection, and brain
removal. The NC formulation contained 0.066 mg LAM, while the
FDNCs formulation contained 0.039 mg LAM. These were the maximum
doses that were able to administer to the animals. This dose was
administered into the right nostril of 160–180 g male Sprague–Dawley
rats (n = 4) with a small spatula. As a control, IV injections of LAM
solution (IV LAM) containing 0.555 mg of API were given to rats
(n = 4). The administration was carried out under isoflurane
anesthesia. At predetermined time points (3, 6, 10, 20, 40 and
60 min) after LAM dosing, the blood of the rats—under deep
isoflurane anesthesia—was collected into heparinized tubes by
cardiac puncture. Then the animals were sacrificed by decapitation
and brain tissues were quickly removed, rinsed in ice-cold PBS, divided
into left and right hemispheres, weighed, and stored at −80 °C until
assayed. The experiments were performed according to the EU
Directive 2010/63/EU for animal experiments and were approved by
the Hungarian Ethical Committee for Animal Research (permission
number: IV/1247/2017).
2.3.8.2. Plasma sample preparation. To 100 µL of plasma samples 20 µL
internal standard solution (0.4 µg/mL, lamotrigine-13C3, d3 in
methanol-water, 50:50, v/v), 20 µL methanol-water mixture (50:50,
v/v) and 100 µL 2 M sodium hydroxide were pipetted, and the samples
were vortexed. For the liquid-liquid extraction 1 mL ethyl acetate was
added to each tube and vortexed for 1 min, shaken at room temperature
for 10 min and left on ice for 5 min. After centrifugation, 300 µL of the
supernatant was transferred to a 1.5 mL glass vial, and evaporated to
dryness at room temperature using a gentle stream of nitrogen. The
samples were resuspended in 50 µL of acetonitrile containing formic
acid (0.1% v/v) and diluted with 0.1% formic acid to a final volume of
400 µL. 20 µL was injected into the LC-MS/MS system for analysis.
Prior to the extraction of the calibration and quality control sam-
ples, 20 µL of a standard solution (6.25 ng/ mL − 8 µg/ mL LAM) was
added to LAM-free pooled rat plasma instead of methanol-water mix-
ture. The rest of the sample preparation steps were the same as
Fig. 1. The process of LPNC and SPNC preparation.
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described above.
2.3.8.3. Brain tissue sample preparation. Brain samples were
homogenized in water (4 mL/g wet tissue weight) on ice 2 times for
30 s with an ULTRA-TURRAX blade-type homogenizer (IKA® Works,
Inc; Wilmington, USA) and for 30 s with a BioLogics Model 150VT
ultrasonic homogenizer (BioLogics Inc, Manassas, USA). The samples
thus prepared were stored at−80 °C until use. On the day of extraction
the samples were thawed, and to 200 µL brain homogenates 20 µL
internal standard solution (0.5 µg/mL, lamotrigine-13C3, d3 in
methanol-water, 50:50, v/v), 20 µL methanol-water mixture (50:50,
v/v) and 20 µL 20% (w/v) trichloroacetic acid (TCA) were added.
Samples were vortexed and centrifuged with 10,000 × g at 20 °C for
10 min and then 100 µL of the supernatant was placed to a new test
tube. LAM was extracted after adding 100 µL 4 M sodium hydroxide
and 1 mL ethyl acetate, by vortexing for 1 min, shaking at room
temperature for 10 min and resting on ice for 5 min. After
centifugation, 700 µL of the supernatant was transferred to a 1.5 mL
glass vial then evaporated to dryness at room temperature. The samples
were resuspended in 50 µL of acetonitril containing formic acid (0.1%
v/v), diluted with 0.1% formic acid to a final volume of 370 µL and
than 20 µL was injected into the LC-MS/MS system for analysis.
Prior to the extraction of the calibration and quality control sam-
ples, 20 µL of a standard solution (7.8125 ng/mL − 10 µg/ mL LAM)
was added to the pooled LAM-free rat brain homogenate instead of
methanol-water mixture. Further sample preparation steps were the
same as described above.
2.3.8.4. LC-MS/MS. The liquid chromatographic separation was
performed on an Agilent 1100 Series HPLC system (Agilent; Santa
Clara, USA) using a Kinetex C18 (2.6 µm 100A, 50 × 2.1 mm) column
(Phenomenex; Torrance, USA). In front of the analytical column, a C18
guard column was used. Water (A) and acetonitril (B) both containing
formic acid (0.1% v/v) were used as mobil phases. A gradient elution
program was used to elute components: gradient started at 13% B,
increased linearly to 90% B in 3 min, kept at 90% B for 2 min, dropped
back to 13% B in 0.1 min and kept at 13% B for 2.9 min. The flow rate
was set at 300 µL/min for the separation and 500 µL/min to wash and
equilibrate the column. The autosampler and the column were
maintained at room temperature.
Samples were analyzed with an on-line connected Q Exactive Plus
quadrupole-orbitrap hybrid mass spectrometer (Thermo Fisher
Scientific; Waltham, USA) equipped with a heated electrospray ion-
source (HESI). It operated in positive mode with the following condi-
tions: capillary temperature 256 °C, S-Lens RF level 50, spray voltage
3.5 kV, sheath gas flow 48, sweep gas flow 2 and auxiliary gas flow 11.
Automatic gain control (AGC) setting was defined as 2 × 105 charges
and the maximum injection time was set to 100 ms. Collision energy
(CE) was optimized and set at 31 eV for LAM and lamotrigine-13C3, d3
(ISTD). The precursor to product ion transition of m/z 256.01→ 108.98
(qualifier), 256.01 → 210.98 (quantifier) for LAM, and m/z 262.04 →
110.99 (qualifier), 262.04→ 217.01 (quantifier) for ISTD were used for
parallel reaction monitoring (PRM).
Data acquisition and processing were performed using Xcalibur™
and Quan Browser softwares (Thermo Fisher Scientific; Waltham, USA).
2.3.8.5. Calculation of drug targeting efficiency. Drug targeting efficiency
(DTE) – relative exposure of the brain to the drug following intranasal
administration vs. systemic administration – was calculated according
to the following formula (Eq. (3)):
The calculation of DTE values
=
( )
( )DTE
IN
IV
AUCbrain
AUCblood
AUCbrain
AUCblood (3)
The value of DTE can range from −∞ to ∞, and the values higher
than 1.0 indicate more efficient drug delivery to the brain following
intranasal administration as compared to the systemic administration
[55].
2.3.8.6. Calculations of the area under the time-concentration curve (AUC)
and statistical analysis. The calculation of area under the curve (AUC) of
the time (min) – concentration (µg/L) curves of each group of animals
were performed with the PKSolver add-in from Microsoft Excel (MS
Office 2010) using the non-compartmental analysis of data after
extravascular input (model #101) of LAM [56]. The AUC values were
calculated using the lineartrapezoidal method. Because of the
incomplete elimination of LAM, the following parameters were not
determined: λ, t1/2, AUC0-inf, AUMC0-inf, Vd, and Cl. All reported data
are means ± SD.
3. Results and discussion
3.1. Identification of factors affecting product quality
The first step before the experiment was to identify and systematize
the most influencing factors that could affect product quality. This
scheme allowed us to design our research plan more effectively, opti-
mizing costs and time. In the Ishikawa-diagram of the NC product we
could identify 4 main groups of influencing factors (Fig. 2): material
characteristics, production method, investigation methods and, ther-
apeutical and regulatory expectations. Among these factors the type
and amount of surfactant, liquid lipid, surface modifier, coating mate-
rial and cryoprotectant, the amount of API and the particle size, its PDI
and the surface characteristics (ZP) of the NCs have the greatest impact
on the quality of the product. The rest of the factors were not found to
be as influencing during the preformulation tests and the literature
review. After setting up the Ishikawa-diagram we decided to set up a
factorial experimental plan, where the type of the coating material and
the lipid was varied. The experiments were optimized for particle size
and PDI.
3.2. Particle size, particle size distribution and surface charge
characterization of NCs
As a first step, the particle size and surface charge of the NCs were
analyzed (Fig. 2). The NCs were always in the 290–380 nm range that is
acceptable according to the FDA regulatory, as the particle size of na-
nosystems have to be between 100 and 1000 nm [57]. Our aim was to
develop NCs that were in the lower part of this range and showed
homogenous particle size population (PDI < 0.2). These requirements
were fulfilled for the NCs only if the liquid lipid: surfactant ratio was
1:1. LAM incorporation resulted in a significant increase in particle size
compared to blank NCs. In all cases, zeta potential values were similar,
positive and close to zero that may be advantageous for mucoadhesion
and mucodiffusion [58]. In the other samples the particle size and PDI
did not meet the criterias that we had set previously and the particles
were not in the nanorange, so thereafter the most promising sample was
tested.
The freeze-dried formulation showed some increase in particle size
and PDI after redispergation (504 ± 3 nm, 0.538 PDI), indicating some
aggregation, that could happen due to the presence of mannitol.
However, this aggregation was not observed on the freeze-dried state
when the powder cake was analyzed with imaging technology as the
particle size showed 179 ± 62 nm. This means that the NCs main-
tained their size after freeze-drying. Another relevant observation was
an increase in zeta potential in the NCs resuspended after freeze-drying,
which can be explained by the density enhancement of chitosan that
was increased due to the increase in particle size and pararelly de-
creased surface area. The 26.5 ± 0.9 value means that the NCs may
have high degrees of stability (see Table 2).
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3.3. Encapsulation efficacy (EE) and drug loading (DL)
The EE of LAM was 58.44%±4.81 in the NCs and the DL was
5.31%±0.67. This is an acceptable level of EE for a nanoformulation,
particularly since it was achieved with a very high drug loading. This
EE means that there is 1.75 mg LAM in 1.5 mL formulation –before
centrifugation– or in one dose of freeze dried cake. This is near to the
lowest marketed dose and could be suitable for administration as if
taken nasally, dose can be decreased.
3.4. Particle morphology
We analyzed LAM-loaded LPNCs (Fig. 3A) and freeze dried SPNCs
(Fig. 3B.) by SEM. The core and shell substructures of the NCs were
clearly visible before freeze drying (Fig. 3A). In both cases, NCs pre-
sented a spherical shape and homogenous distribution. There was no
sign of non-encapsulated, crystalline LAM around the NCs and there
was no sign of aggregation in the mannitol matrix, so the pictures in-
dicated good particle stability and no warnings regarding drug seg-
gregation.
3.5. In vitro drug release study
The in vitro release study showed faster release of LAM in the case of
NCs formulation compared to pure LAM powder (Fig. 4). We could
detect more than 20% released LAM after 5 min and ~60% LAM after
15 min; afterwards a drug release plateau was observed. The FDNCs
released the drug a slower than NCs but markedly faster than the drug
powder. In this case ~40% LAM was released after 10 min, and 50%
after 15 min, a point where the release started to level-off. At 15 min,
both NCs formulations released between 2.5 and 3-fold more LAM than
the drug powder. For nasal administration, the first four points are the
most important, because the mucociliary clearance renews the nasal
mucus every ~15 min, thus limiting the API residence time at this site
[59,60]. In this sense, the fast release of LAM from the nanoformula-
tions can be considered an advantageous characteristic for nasal de-
livery. Moreover, the use of chitosan may extend the residence time, the
bioadhesion which means that the formulation could have enough time
to get into the CNS and can reach enhanced absorption [24,61].
3.6. In vitro permeability study
Next, we performed a permeability study to compare how the dif-
ferent formulations could modify the capacity of LAM for crossing
biological barriers (Fig. 5). In case of nasal administration, it is im-
portant to achieve a high permeability rate through the mucosa, which
means that the API reaches its target more efficiently. NCs and FDNCs
formulations performed similarly well in this experiment, and much
Fig. 2. Ishikawa-diagram of the NC product.
Table 2
Results of the particle size and surface characterization of the NCs.
Z-average (d. nm) PDI Zeta potential (mV)
Blank NCs after centrifugation (2:1 ratio) 2815 ± 159 0.795 0.99 ± 0.4
LAM NCs after centrifugation (2:1 ratio) 1210 ± 68 0.773 1.3 ± 0.1
Blank NCs after centrifugation (1:2 ratio) 1477 ± 72 0.643 0.80 ± 0.3
LAM NCs after centrifugation (1:2 ratio) 1399 ± 59 0.950 0.94 ± 0.5
Blank NCs after centrifugation (1:1 ratio) 294 ± 9 0.175 0.39 ± 0.2
LAM NCs after centrifugation (1:1 ratio) 305 ± 7 0.188 1.0 ± 0.3
FDNCs Freeze-dried: 179 ± 62
After redispergation: 504 ± 3
0.538 26.5 ± 0.9
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better than a LAM powder, which achieved the lowest amount of per-
meated drug. In the case of the NCs formulations ~25 µg/cm2 LAM
diffused through the cellulose ester membrane, which is 2.5 times
higher than the amount of drug diffused from the raw powder for-
mulation. This was a remarkably high amount if we take into con-
sideration that an average human nasal mucosa is around 150–200 cm2
[62].
Tha calculated Flux (J) and permeability coefficient (Kp) values
(Table 3). The Flux shows how much API can diffuse through the
membrane per hour and surface unit, while Kp is the Flux-donor phase
ratio. The results of the table shows that tha LAM could diffuse in
higher amount through the membrane to the acceptor phase from the
NC formulations than from the powder, and that there was no sig-
nificant difference between both nanoformulations. These results vali-
dated the previous observations on drug diffusion, as the NC formula-
tions showed higher values for these parmaters than the powder.
Compared to a previously reported, nanosized LAM containing nasal
powder formualtion, the Flux is lower, but the permeability coefficient
values predict good permeability through biological barriers [49].
3.7. In vivo drug release study
In a final step, we performed the in vivo administration of the LAM
formulations and we performed PK analysis both in the brain and in the
blood (Figs. 6 and 7, respectively). Nasal administration of LAM in NCs
achieved higher brain drug concentrations than FDNCs. Also, the cmax
of NCs was higher (0.23 µg/brain g) than after the administration of
FDNCs (0.07 µg/brain g). The tmax was 60 min in the case of NCs, while
it was 3 min when FDNCs were given to the rats. Indeed, NCs resulted in
significantly higher AUC values (11.65 ± 1.03 min*µg/brain g) than
FDNCs (2.06 ± 1.11 min*µg/brain g), while the AUC value of IV ad-
ministration was 250.603 ± 7.66 min*µg/ brain g. The ratio of AUC
values between the liquid and the solid NCs was 5.65, which means that
this formulation was capable of providing better drug absorption. In
any case, LAM was present in the CNS shortly after administration since
it was detected there even at the 3 min extraction point. This time
seems too short for LAM to be absorbed and to cross through the BBB,
which indicates a possible axonal and paracellular transport of the drug
[63]. Besides, in the case of FDNCs, the drug would take more time to
be absorbed to the systemic circulation (Fig. 7.) through the nasal
Fig. 3. The morphology of LAM loaded NCs (Picture A.) and FDNCs (Picture B.)
Fig. 4. In vitro drug release from different NCs formulations and LAM powder.
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mucosa, but it is still detected in the CNS. FDNCs showed very constant
LAM levels in the CNS after the first 10 min, and we hypthesize that this
could be due to the presence of parallel transport mechanism of axonal
transport and access through the BBB.
We also determined the concentration of LAM in the blood plasma
vs. time (Fig. 7). The plasma concentration of LAM was significantly
higher for the NCs group than for the FDNCs group, an this was parti-
cularly remarkable in the 3 min datapoint: 0.18 ± 0.032 µg/mL vs.
0.01 ± 0.002 µg/mL LAM concentration for NCs and FDNCs, repec-
tively. This could be explained by the fact that the API reached the
systemic circulation without passing through the liver. Another possible
explanation of the relatively high absorption of liquid NCs is that the
liquid could spread over a larger surface that caused higher plasma
concentrations. Moreover, another possible explanation of the poor
permeation of the FDNCs is that in the nasal cavity the amount of water
is limited. As the solid particles needs to be solubilized before per-
meation, this limited amount of water can retard or even limit the ex-
tent of the absorption. The ratio of AUC values shows that the API from
the liquid NCs reached the plasma 12.28-fold more than the API in
freeze-dried NCs (AUC(NCs) = 6.13 ± 0.52 min*µg/mL plasma;
AUC(FDNCs) = 0.50 ± 0.16 min*µg/mL), but they were well below the
IV formulation (125.08 ± 17.46 min*µg/mL). The cmax value was
much higher (0.18 µg/mL) in the case of NCs, which was detected after
3 min (tmax) than it was in the case of FDNCs administration (0.14 µg/
mL), which was detected after 10 min.
Table 4. represents the calculated values of the investigation. The
brain:plasma ratios of the NCs and FDNCs were 1.90, and 4.13, re-
spectively. This means that the API was more concentrated in the CNS
than in blood plasma. The fact that this value is higher for the FDNCs
than for the NCs indicates that this concentration ratio is not only de-
pendent of drug biodistribution, but rather on other biopharmaceutical
processes. We think that this higher ratio achieved with FDNCs could
indicate a higher contribution of paracellular and direct axonal drug
transport for this formulation as compared to NCs.
The cerebral drug targeting efficiency index (DTE) reflects the re-
lative accumulation of the drug in the brain following intranasal
Fig. 5. In vitro permeability study of LAM in different formulations.
Table 3
Calculated Flux (J) and permeability coefficient (Kp) values for the different
LAM formulations.
J (µg/cm2/h) Kp (cm/h)
LAM 35.29 ± 8.92 0.011 ± 0.002
NCs 41.29 ± 5.47 0.023 ± 0.005
FDNCs 42.96 ± 4.13 0.03 ± 0.005
Fig. 6. The concentration values of LAM in the brain tissues.
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administration as compared to systemic administration. DTE data was
around 1.0 in case of NCs, which means that LAM presented in similar
concentrations in plasma and brain tissues, respectively. As for the
FDNCs, the LAM could reach the brain tissues two times more effi-
ciently via axonal transport, than through the systemic circulation,
which is indicated by the value above 2.0. This resulted in remarkable
absorption through the nasal mucosa directly into the CNS and paral-
lelly resulted in poor transepithelial absorption into the systemic cir-
culation in case of the solid state sample.
4. Conclusion
The aim of this study was to develop and investigate novel, LAM
containing NCs. After preliminary experiments and size optimization,
chitosan coated NCs with LAM were formulated both as a liquid sus-
pension and as freeze-dried powder. The particle size of the NCs was
always under 500 nm that meets with the particle size criteria of na-
nosystems according to regulatory guidelines and this nanosize was
maintained after freeze-drying. The zeta potential was almost neutral in
NCs, that could have a positive effect on mucoadhesion and muco-
diffusion, and turned out to be positive in FDNCs, that could advanta-
geous as in the blood stream, the particles could not be rapidly opso-
nized and cleared by macrophages. The encapsulation efficiency was
acceptable, while the NCs were spherical and homogenous with no sign
of aggregation in both samples. LAM was released quickly from both
NCs formulations, with 50% payload released after 15 min, which
predicted great release in vivo. The permeation rate of LAM was also
higher for the NC samples than for LAM in powder form. In vivo studies
showed that LAM could reach the brain in significant amounts, parti-
culary for the liquid state NCs formulation that also showed remarkably
high blood plasma levels of the API. The kinetics and biodistribution
ratio of the drug between brain and plasma suggest that there is axonal
transport involved in drug absorption, which means that the LAM can
reach its site of action in an amount sufficient for effect. All in all it can
be said, that the novel, NC formulation can offer a great alternative for
LAM administration into the CNS in consdiderably high amount and
with the use of this kind of nanoformulation the advantages of
nanosystems and nasal delivery can be combined.
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